Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VirbacCHIX:VIRPP 95 Return-on-Tangible-Asset is 10.33% as of Dec. 2025, which is 9% below its 10-year median of 11.37. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €368.81. The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Virbac ranks better than 82.14% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Virbac's annualizedNet Income for the quarter that ended in Dec. 2025 was €137 Mil. Virbac's average total tangible assets for the quarter that ended in Dec. 2025 was €1,326 Mil. Therefore, Virbac's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 10.33%.
The historical rank and industry rank for Virbac's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:VIRPp'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -0.37 Med: 11.37 Max: 17.36
Current: 11.39
During the past 13 years, Virbac's highest Return-on-Tangible-Asset was 17.36%. The lowest was -0.37%. And the median was 11.37%.
CHIX:VIRPp's Return-on-Tangible-Asset is ranked better than 82.14% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.14
vs CHIX:VIRPp: 11.39
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Virbac Return-on-Tangible-Asset Related Terms
Virbac Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Virbac's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VIRPP vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Virbac's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Virbac's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 10.33% mean?
Virbac (CHIX:VIRPP) has a Return-on-Tangible-Asset of 10.33% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Virbac and its competitors. This is near median its historical median of 11.37. According to the industry distribution chart, Virbac ranks #180 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Virbac's Return-on-Tangible-Asset too high?
Virbac's current Return-on-Tangible-Asset of 10.33% is near median its 10-year median of 11.37. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.14. Virbac's value of 10.33% is 229% above this industry median. Based on the distribution chart, Virbac ranks #180 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #180 out of 1008 companies for Return-on-Tangible-Asset. This places Virbac in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.14. Virbac's value of 10.33% is 229% above this benchmark. While the company's 10-year median is 11.37 vs. the industry median of 3.14, Virbac has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.14, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current Return-on-Tangible-Asset of 10.33% is 229% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current Return-on-Tangible-Asset is 10.33%, which is near median its own 10-year median of 11.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Return-on-Tangible-Asset of 10.33%. The stock's GF Value™ is €368.81, compared to a current price of €334.00 — trading 9.4% below its estimated fair value. The current Return-on-Tangible-Asset is 10.33%, which is near median its 10-year median of 11.37 and 229% above the Drug Manufacturers industry median of 3.14. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Return-on-Tangible-Asset is 10.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (CHIX:VIRPP) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be undervalued.
The current stock price of €334.00 is trading 9.4% below its estimated GF Value™ of €368.81.
Key valuation signals for CHIX:VIRPP:
Return-on-Tangible-Asset: 10.33% (near median its 10-year median of 11.37)
GF Value™: €368.81 vs. price of €334.00 (9.4% below fair value)
Industry Position: 229% above the Drug Manufacturers median (#180 of 1008)
No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score
Get the complete analysis for CHIX:VIRPP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VIRPP has been successfully added to your 
